Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC.
In: Medical Letter on the CDC & FDA, 2024-05-10, S. 26-26
serialPeriodical
Zugriff:
Ractigen Therapeutics has received FDA approval for their saRNA therapy, RAG-01, which targets non-muscle invasive bladder cancer (NMIBC). This therapy activates the p21 tumor suppressor gene, which plays a crucial role in stopping the growth of cancer cells. RAG-01 is the first therapy of its kind to specifically target and activate this gene. The approval allows for the launch of clinical trials in the United States, following a successful Phase I trial in Australia. NMIBC represents a significant unmet need in bladder cancer therapy, and RAG-01 offers a promising new option for patients. [Extracted from the article]
Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC.
|
---|---|
Zeitschrift: | Medical Letter on the CDC & FDA, 2024-05-10, S. 26-26 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4648 (print) |
Sonstiges: |
|